Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection

Damme, Claire van; Berlingin, E.; Saussez, Sven; Accaputo, O

doi:10.1111/jdv.16523

Cited by 118 publications

(150 citation statements)

References 6 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Two cases have been reported from Belgium—a 39‐year‐old women and a 71‐year‐old man who presented with urticarial rash and pyrexia. Both were tested positive for SARS‐CoV‐2‐RNA 29 . Spanish groups reported an urticarial rash without mucosal involvement in a 32‐year‐old female that started 6 days after the onset of COVID‐19 disease and another group 10 days after onset of COVID‐19 in a 28‐year‐old woman.…”

Section: Chickenpox‐like Rashmentioning

confidence: 99%

Cutaneous signs in COVID ‐19 patients: A review

Wollina

Karadağ

Rowland‐Payne

et al. 2020

Dermatologic Therapy

260

286

View full text Add to dashboard Cite

Coronavirus disease pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the epithelium of the airways.With the increasing involvement of dermatologist in management of this crisis, cutaneous symptoms gained more and more attention. In this review, we will describe cutaneous symptoms of patients of all ages in association with COVID-19.We will focus on such disorders that are caused by direct action of SARS-CoV-2 on tissues, complement, and coagulation system and on nonspecific eruption of the systemic viral infection. Drug-induced reactions are only mentioned in the differential diagnoses. Although more systematic investigations are warranted, it becomes clear that some symptoms are clinical signs of a milder COVID-19 course, while others are a red flag for a more severe course. Knowledge of the cutaneous manifestations of COVID-19 may help in early diagnosis, triage of patients, and risk stratification.

show abstract

Section: Chickenpox‐like Rashmentioning

confidence: 99%

Cutaneous signs in COVID ‐19 patients: A review

Wollina

Karadağ

Rowland‐Payne

et al. 2020

Dermatologic Therapy

260

286

View full text Add to dashboard Cite

show abstract

“…The characteristics of skin lesions in patients with COVID-19, as described recently in case reports or case series, are summarized in the Table 1 [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ,…”

Section: Introductionmentioning

confidence: 99%

Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature

2020

View full text Add to dashboard Cite

In recent weeks, several reports have emerged of skin lesions with different clinical presentations in COVID-19 cases. All dermatologists should be aware of these cutaneous lesions, which may be early clinical symptoms of infection. We reviewed the literature on cutaneous manifestations in the PubMed database from December 2019 and June 2020. From the cases described as case reports or series in 57 recent articles, it appears that skin lesions (i) are highly varied, (ii) may not be related to the severity of the condition and (iii) resolve spontaneously in a few days. The frequency of these lesions in COVID-19 patients varies between 1.8% and 20.4%. The major clinical forms described were maculopapular eruptions, acral areas of erythema with vesicles or pustules (pseudochilblain), urticarial lesions, other vesicular eruptions and livedo or necrosis. The lesions were mainly localized in the trunk and extremities. The majority of patients were male, aged between 4.5 and 89 years. A minority of the patients were children presenting with acral, chilblain-like lesions, papulo-vesicular eruptions or Kawasaki disease-like pediatric inflammatory multisystem syndrome. The mean duration of the lesions was a few days, but some lasting as little as 20 min and others as long as four weeks have been reported. The mean latency time in the majority of cases was between 1 and 14 days; however, in some patients, lesions appeared 2 to 5 days before the onset of COVID-19 symptoms. The histopathological features of these lesions also vary, corresponding to the diversity of clinical manifestations. These features underline the nature of epidermal and dermal vascular lesions—and in severe cases, microvascular injury and thrombosis—associated with COVID-19, and provide important clues to their pathological mechanisms.

show abstract

“…Also, they were easy to treat with second generation antihistaminics and paracetamol. [12][13][14] Regarding exanthematous lesions, a varicella-like exanthem was reported in a multicenter case series of 22 COVID-19-positive patients. Median onset of lesions was 3 days after symptom onset with subsequent resolution over 8 days.…”

Section: Dermatological Manifestations Of Covid-19mentioning

confidence: 99%

Dermatological Manifestations of COVID-19: A Brief Review

Kaur¹

2020

ANAMS

View full text Add to dashboard Cite

The emphasis so far during the COVID-19 pandemic has been on the respiratory manifestations with little attention being paid to cutaneous manifestations. The novel coronavirus has a wide spectrum of cutaneous manifestations which are broadly divided into exanthematous and vasculopathic type of lesions. The effects of this novel virus on the integumentary system cannot be underestimated as it can mimic various types of viral skin lesions. Thus, dermatologists should have knowledge about COVID-19 disease presentations and which differential diagnosis to consider if they encounter skin lesions in a patient who is known or suspected to have COVID-19. Patient evaluation and workup also needs to be modified during the time of this pandemic. Immunosuppressive/immunomodulatory drugs which are rampantly used in dermatological practice, must be used only after weighing their risks and benefits during the COVID-19 era. Personal Protective Equipment has to be worn when coming in contact with a suspected or a proven case of COVID-19. However, its use itself is associated with dermatological side effects which should be known to dermatologist practising during the COVID-19 era. Teledermatology can go a long way in circumventing these issues and it should be made more accessible, especially in remote areas. Another future recommendation could be setting up of a national level organization or group for recording dermatological data related to COVID-19.

show abstract

Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection

Cited by 118 publications

References 6 publications

Cutaneous signs in COVID ‐19 patients: A review

Cutaneous signs in COVID ‐19 patients: A review

Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature

Dermatological Manifestations of COVID-19: A Brief Review

Contact Info

Product

Resources

About